Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development

by Anand Rotte, Srikumar Sahasranaman, Nageshwar Budha
Published 2021-09-01

Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach

by Kapil Gadkar, James Lu, Srikumar Sahasranaman, John Davis, Norman A. Mazer, Saroja Ramanujan
Published 2016-01-01

Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator

by Kun Wang, Xueting Yao, Miao Zhang, Dongyang Liu, Yuying Gao, Srikumar Sahasranaman, Ying C. Ou
Published 2021-05-01

Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies

by Ying C. Ou, Lucy Liu, Bilal Tariq, Kun Wang, Ashutosh Jindal, Zhiyu Tang, Yuying Gao, Srikumar Sahasranaman
Published 2021-03-01